Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAcute LeukemiasAggressive LymphomasT-Cell and NK-Cell NeoplasmsDiseaseAcute Lymphoblastic LeukaemiaNHL, T-cell typeNHL, T-Cell Type, Adult T-Cell Leukemia or LymphomaNHL, T-Cell Type, Anaplastic Large CellNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positiveNHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negativeNHL, T-Cell Type, AngioimmunoblasticNHL, T-Cell Type, Enteropathy TypeNHL, T-Cell Type, HepatosplenicNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupCD30+T-ALLICD10C84.4C84.5C84.6C84.7C86.1C86.2C86.5C91.0-C91.5-MeSHLymphoma, Primary Cutaneous Anaplastic Large CellLymphoma, T-CellLymphoma, T-Cell, CutaneousLymphoma, T-Cell, PeripheralPrecursor Cell Lymphoblastic Leukemia-LymphomaSequenceT-ALL: Hyper-CVAD (CYCL300/VNCR2/DOXO50/DEXA40)/RITU375, ALL/NHL, C1 (PID2061) -|- C2 (PID2064) -|- C3 (PID2061) -|- C4 (PID2064) -|- C4N (PID2083) -|- C5 (PID2063) -|- C5N (PID2083) -|- C6 (PID2065) -|- C7 (PID2063) -|- C8 (PID2065) -|- Month 1-5 (PID2072) -|- Month 6 (PID2083) -|- Month 7 (PID2083) -|- Month 8-17 (PID2072) -|- Month 18 (PID2074) -|- Month 19 (PID2061) -|- Month 20-30 (PID2072)ChemotherapyChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideNelarabinePeg asparaginasePrednisoloneChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideNelarabinePeg asparaginasePrednisoloneChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideNelarabinePeg asparaginasePrednisoloneChemo-substanceBrentuximab vedotinCarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideNelarabinePeg asparaginasePrednisoloneNo. Substances24 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMesnaParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMesnaParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMesnaParacetamolPegfilgrastimSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMesnaParacetamolPegfilgrastimNo. Substances46Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineTherapy phaseMaintenanceTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlDiarrheaEmetogenicity (MASCC/ESMO)Febrile NeutropeniaInfectionsNeuropathyNeutropeniaPyrexiaThromboembolic Event only studiesPublicationAuthorHorwitz SRausch CRVan de Wyngaert ZDiseaseHochmaligne B-ALL/T-ALL und Burkitt-Lymphom bei Erwachsenen, Erstlinieperipheres T-Zell Lymphom, CD30+, Erstlinie, ECOG 0-2rezidiviertes oder refraktäres peripheres T-Zell Lymphom, CD30+, ECOG 0-3OriginDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, TexasHématologie clinique et thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, FranceMemorial Sloan Kettering Cancer Center, New York, ECHELON-2 study groupProtocols in Revision 3 protocols foundProtocols under revision.BV-ICE - Brentuximab Vedotin 1.8 / Etoposide 100 / Carboplatin 5 / Ifosfamide 5, T-cell Lymphoma (PID2420 V1.0)Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma (PID1204 V1.0)Nelarabine 650 / Peg-asparaginase 1500, T-ALL, maintenance, month 6, 7 (PID2083 V1.1)
